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Abstract
Introduction: There is little evidence to guide the timing of delivery of women with 
early-onset severe preeclampsia. We hypothesize that immediate delivery is not in-
ferior for neonatal outcome but reduces maternal complications compared with tem-
porizing management.
Material and methods: This Dutch multicenter open-label randomized clinical trial 
investigated non-inferiority for neonatal outcome of temporizing management as 
compared with immediate delivery (TOTEM NTR 2986) in women between 27+5 and 
33+5 weeks of gestation admitted for early-onset severe preeclampsia with or with-
out HELLP syndrome. In participants allocated to receive immediate delivery, either 
induction of labor or cesarean section was initiated at least 48 hours after admission. 
Primary outcomes were adverse perinatal outcome, defined as a composite of severe 
respiratory distress syndrome, bronchopulmonary dysplasia, culture proven sepsis, 
intraventricular hemorrhage grade 3 or worse, periventricular leukomalacia grade 2 or 
worse, necrotizing enterocolitis stage 2 or worse, and perinatal death. Major maternal 
complications were secondary outcomes. It was estimated 1130 women needed to be 
enrolled. Analysis was by intention-to-treat.
Results: The trial was halted after 35 months because of slow recruitment. Between 
February 2011 and December 2013, a total of 56 women were randomized to imme-
diate delivery (n = 26) or temporizing management (n = 30). Median gestational age 
at randomization was 30 weeks. Median prolongation of pregnancy was 2 days (inter-
quartile range 1-3 days) in the temporizing management group. Mean birthweight was 
1435 g after immediate delivery vs 1294 g after temporizing management (P = .14). 
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1  | INTRODUC TION
Preeclampsia is characterized by the clinical symptoms of hyperten-
sion arising after 20 weeks of gestation and involvement of one other 
organ system. Preeclampsia is associated with increased maternal 
and perinatal morbidity and mortality.1 The ultimate and only cure is 
delivery of the placenta, thus ending pregnancy. Late preeclampsia, 
usually defined as onset of the disease after 34 weeks of gestation, 
is less prone to complications, both because the disease in general 
tends to have a milder course and because pregnancies do not pro-
ceed until complications occur because labor is induced.2 Three 
trials have been published on temporizing management of preec-
lamptic pregnancies after 34 weeks.3,4 Between 34 and 37 weeks of 
gestation, temporizing management is associated with better peri-
natal outcome with an acceptable increase in maternal morbidity.4 
However, after 37 weeks the advantages of immediate delivery are 
more evident, with reduction in hypertensive episodes and lower 
cesarean section rates.3 A recent British trial showed benefits of im-
mediate delivery without compromising neonatal outcome.5
In early-onset preeclamptic pregnancies, usually defined 
as onset of the disease before 34 weeks of gestation, there is 
a greater clinical dilemma, as iatrogenic preterm birth at very 
early gestational age can substantially contribute to severe ad-
verse neonatal outcomes due to prematurity, and a temporizing 
management strategy may reduce that disease burden.6 In the 
Netherlands, temporizing management in early-onset severe pre-
eclampsia has been standard care for decades.7,8 In the last decade 
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The adverse perinatal outcome rate was 55% in the immediate delivery group vs 52% 
in the temporizing management group (relative risk 1.06; 95% confidence interval 
0.67-1.70). In both groups there was one neonatal death and no maternal deaths. 
In the temporizing treatment group, one woman experienced pulmonary edema and 
one placental abruption. Analyses of only the singleton pregnancies did not result in 
other outcomes.
Conclusions: Early termination of the trial precluded any conclusions for the main 
outcomes. We observed that temporizing management resulted in a modest prolon-
gation of pregnancy without changes in perinatal and maternal outcome. Conducting 
a randomized study for this important research question did not prove feasible.
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Key message
This randomized controlled trial in women with early-onset 
severe preeclampsia investigated non-inferiority for neo-
natal outcome of temporizing management vs immediate 
delivery. The trial was stopped after 35 months because of 
slow recruitment.
TA B L E  1   Randomized controlled trials evaluating expectant or temporizing management compared with immediate delivery in early-
onset severe preeclampsia









Odendaal10 b,c  1990 38 28-34 27 NA 7.1
Sibai11 b,c  1994 95 28-32 4 NA 15.4
Mesbah13 c  2003 30 28-33 NA NA NA
Vigil-de Gracia12 b  2013 267 28-33 25 56 8.1
n, number of inclusions; NA, not available.
aPercentage of morbidity in the temporizing management group that was not statistically different from the immediate delivery group. In most 
studies it was not reported whether there was one or more morbidity. 
bHELLP syndrome was excluded. 
cMultiple pregnancies were excluded. 
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this policy has gradually been changing toward a more interven-
tionist approach.9
So far, four randomized controlled trials have addressed the clini-
cal dilemma of timing of delivery in women with severe preeclampsia 
between 28 and 34 weeks of gestation (Table 1).10-13 Study popula-
tions were too small, ranging from 30 to 267 women, and at least 
three studies did not include preeclamptic women with HELLP syn-
drome.10-12 All studies planned delivery in the active management 
arm 48 hours after administration of corticosteroid medication. 
Expectant management leads to a prolongation of pregnancy of 5.8-
12.8 days in these studies. The two oldest studies, with a similar 
prolongation of pregnancy as in the two more recent studies, found 
stronger effects on adverse perinatal outcomes because composite 
neonatal outcome decreased from 75% to 25%. The most recent and 
largest study could not confirm this effect despite a prolongation in 
the expectant management group of 8.1 days. This may be due to 
the concomitant effects of continuously ameliorating neonatal care 
for preterm babies.14
The objective of this randomized controlled open-label non-in-
feriority study was to compare temporizing management with 
immediate delivery in pregnant women with severe early-onset 
preeclampsia. We hypothesized that immediate delivery would not 
be inferior regarding neonatal morbidity and mortality but might re-
duce maternal morbidity.
2  | MATERIAL AND METHODS
The TOTEM study (TempOrize or TErMinate pregnancy in women 
with severe preeclampsia) was an open-label, multicenter rand-
omized controlled trial performed within the Dutch Consortium for 
Healthcare Evaluation and Research in Obstetrics and Gynecology. 
Nine of the 10 Dutch perinatal centers participated.
2.1 | Participants
Women with severe early-onset preeclampsia with a gestational age 
between 27+5 and 33+5 weeks were eligible for inclusion. Preeclampsia 
was diagnosed according to the contemporary definition of the 
International Society for the Study of Hypertension (ISSHP): hy-
pertension (≥140/90 mmHg) with proteinuria (>0.3 g/24 hours).15 
Severe preeclampsia was modified from the ACOG criteria for se-
vere preeclampsia and defined as preeclampsia in combination with 
one or more of the following criteria9:
1. Clinical symptoms such as cerebral or visual disturbances (eg 
headache) and/or right upper quadrant or epigastric pain.
2. Laboratory abnormalities: thrombocytopenia (<100 × 109/L) and/
or impaired liver function tests aspartate transaminase/alanine 
transaminase (ASAT/ALAT) ≥40 U/L and lactate dehydrogenase 
(LDH) ≥600 U/L and/or haptoglobin <0.2 g/L.
3. Severe hypertension (systolic ≥160 mm Hg and/or diastolic 
≥110 mm Hg).
Women had to be ≥18 years and have a working knowledge of 
the Dutch language, and the fetus had to have an estimated fetal 
weight ≥500 g.
Exclusion criteria were fetal distress, clinically relevant pulmo-
nary edema, suspected placental abruption, eclampsia, major fetal 
congenital anomalies, fetal death, therapy-resistant hyperten-
sion, (sub)capsular liver hematoma, acute fatty liver of pregnancy, 
renal failure (creatinine clearance <40 mL/min), cerebrovascu-
lar incident, a thromboembolic event or other severe maternal 
complications.
All eligible women were treated with intravenous magnesium 
sulfate for at least 24 hours after admission; if necessary, antihy-
pertensive medication to stabilize blood pressure and one course of 
corticosteroid therapy were given. Laboratory tests were routinely 
performed. In case of abnormalities, laboratory tests were repeated 
daily. Finally, fetal heart rate monitoring was performed at least 
twice a day during admission. Participants were treated according to 
the guideline on hypertensive disorders in pregnancy of the Dutch 
Society for Obstetrics and Gynecology.16
2.2 | Interventions
Eligible women were counseled on the day of admission by dedi-
cated research nurses or by accredited clinical staff. A neonatolo-
gist also consulted every woman and her partner within 24 hours 
after admission. At admission, women had an abdominal ultrasound 
performed to rule out fetal congenital anomalies and to estimate 
fetal weight. Participating women signed a written consent the day 
after admission and randomization took place, and were allocated 
to immediate delivery or to temporizing management. After enroll-
ment, demographic characteristics, medical history and all other 
data were recorded in case report forms by research nurses.
2.2.1 | Immediate delivery
At least 24 hours after randomization in the immediate delivery 
group, labor induction was started or an elective cesarean section 
was performed. Labor induction was performed according to local 
protocol by either mechanical or medical methods.
2.2.2 | Temporizing management
In the temporizing management group, the following strict criteria 
for intervention were used:
1. signs of fetal distress (defined as spontaneous, repeated, per-
sistent unprovoked decelerations on the cardiotocogram),
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2. no improvement within 3 days of the initial HELLP syndrome or 
recurrence,
3. clinical maternal deterioration and complications as per the earlier 
mentioned exclusion criteria.
In all women in the temporizing management arm, pregnancy 
was terminated if the patient reached a gestational age of 34 weeks, 
independent of complications.
After delivery, in both groups, all neonates were assessed by a 
neonatologist and, if necessary, admitted to the neonatal intensive 
care unit.
In the postpartum period, high blood pressure was treated with 
antihypertensive medication to attain systolic values of ≤140 mm Hg 
and diastolic values of ≤90 mm Hg.
2.3 | Objectives
The study was designed as a noninferiority effectiveness trial with 
a neonatal safety outcome and a secondary maternal outcome. We 
postulated that immediate delivery would be noninferior to expectant 
management for the risk of neonatal morbidity as defined by a com-
posite outcome measure of neonatal morbidity and perinatal mortality.
2.4 | Outcomes
The primary endpoint was adverse perinatal outcome, defined as 
a composite of neonatal morbidity and mortality: with at least one 
or more of the following neonatal complications: severe respiratory 
distress syndrome, chronic pulmonary disease (oxygen therapy be-
yond 36 weeks’ postconceptional age), intraventricular hemorrhage 
grade 3 or more, periventricular leukomalacia grade 2 or more, 
proven sepsis or necrotizing enterocolitis stage 2 or worse and peri-
natal mortality.
Secondary neonatal endpoints were perinatal death, each of the 
components of the primary endpoint, birthweight, Apgar scores, ar-
terial umbilical pH, number of days on additional oxygen, days on 
supported ventilation, use of surfactant, number of days in intensive 
care, total days in hospital. Bailey-3 assessments were performed at 
2 years corrected age.
Secondary maternal outcomes were adverse composite ma-
ternal outcome and its individual components pulmonary edema, 
eclampsia, adult respiratory distress syndrome, cerebrovascular 
accident, placental abruption, liver hematoma or rupture, acute 
fatty liver of pregnancy, renal insufficiency, thromboembolism or 
maternal death.
2.5 | Sample size
Assuming an incidence of the primary composite outcome of neona-
tal morbidity and mortality of 12% and using a noninferiority margin 
of 5%, we needed to recruit two groups of 523 women (1046 women 
in total) to achieve 80% power at 95% significance. This percentage 
was based on the results of a previous study in the Netherlands.17
For the secondary aim to show that delivery 48 hours after ad-
mission would reduce the maternal complications from 20% to 10%, 
two groups of 215 women (430 women in total) were needed for a 
power of 80% and 95% significance.
Therefore, the sample size to be achieved was chosen as 1046 
patients. To allow for losses to follow-up, the sample size was 
rounded up to 1130 patients.
Interim analyses were scheduled after every 150 randomizations.
2.6 | Randomization
Randomization was done using an online randomization system, 
with randomly permuted blocks, stratification by gestational age 
(lower or higher than 31 weeks) and by center.
2.7 | Statistical analyses
Analysis was planned to be done on the intention-to-treat and per-
protocol populations. After the trial had been stopped, the final 
analyses were only conducted on the intention-to-treat population 
because of the small numbers.
For all outcomes we estimated relative risks (RR) or mean, me-
dian or differences, with 95% confidence (CI) intervals. Descriptive 
statistics were used to describe baseline measures. Significance was 
tested using chi-square tests (based on maximum likelihood), Fisher’s 
exact tests, t test, or Mann-Whitney U tests as appropriate. An alpha 
of 0.05 was used for statistical significance. For neonatal outcomes 
in multiple pregnancies, the outcome was assessed per pregnancy, 
and thus deemed present if at least one neonate was affected. No 
imputation was done for missing data. Given the size of the trial at 
time of stopping, it was not possible to account for the stratifica-
tion factors from randomization in the analyses. Data were analyzed 
using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
2.8 | Ethical approval
The study is registered under TOTEM NTR 2986 and approved by 
the Institutional Review Board of the Erasmus MC (MEC-2008-151, 
8 April 2010) and the board of directors of the participating centers. 
The study complies with the Declaration of Helsinki.
3  | RESULTS
From February 2011 until December 2013, 56 women were in-
cluded in the trial. Because of the slow recruitment rate, the trial 
was halted in December 2013. At that time, 26 women had been 
     |  113DUVEKOT ET al.
randomized for immediate delivery and 30 women for temporiz-
ing management. There were several reasons for the slow recruit-
ment rate. Most importantly, the number of eligible women was 
not as high as expected. In the largest center, 73 women were 
eligible during the study period. Extrapolating this number to the 
remaining part of the Netherlands, 350-370 women were eligible 
in the whole country (110-120 women per year). Almost half of 
the women refused to participate, which is a number that can be 
expected in trials with this format. Forty-three women refused to 
participate but 27 of those women gave permission to use their 
data. Some women refused to participate because there was a 
possibility that they would be randomized to an unwanted treat-
ment. About half of the women who refused wanted to be deliv-
ered immediately because of their fear of complications. The other 
half of the women wanted to wait to improve the condition of their 
babies. Two women did not want to participate in a study at all. 
Also, especially at the start of the trial, obstetricians were reluc-
tant to participate and to change their normal treatment. In nine 
women, the trial was not discussed and were missed for randomi-
zation. Finally, 21 women were randomized in this center, about 
one-third of all eligible women. This was a relative large number of 
inclusions, which is usually seen in multicenter trials in the center 
of the principal investigator. Thirty-eight women delivered within 
24 hours after admission and could not be recruited. Most of these 
women were delivered because of suspected fetal distress after 
maternal stabilization.
Baseline characteristics were comparable between groups 
(Table 2 and Table S2). Chronic hypertension and multiple pregnan-
cies were slightly more common in the immediate delivery group. 
Nulliparity was more prevalent in the temporizing management 
group. Six women had been diagnosed with preeclampsia before 
28 weeks and were temporized until 28 weeks before they were 
randomized.
In all, 71 of all women had clinical symptoms: 38% with labora-
tory abnormalities and 62% with severe hypertension at inclusion.
We were unable to compare baseline characteristics for random-
ized and non-randomized women because data of non-randomized 
women were not reliably recorded.
Data on the course of pregnancy and delivery are specified in 
Table 3. There was a small difference in the randomization to deliv-
ery interval between both groups (median 2 days, interquartile range 
[IQR] 1-3 days).
In the temporizing management group, 11/30 pregnancies were 
terminated for fetal compromise and 19/30 for maternal condition. 
There were no cases of prespecified indications for delivery in this 
group. No deliveries took place during the first 24 hours after ran-
domization in this group.
In the immediate delivery group, seven women delivered within 
24 hours after randomization, four of whom also had suspected fetal 
distress. One patient delivered 4 weeks after randomization because 
the clinical situation improved after randomization to non-severe 
preeclampsia and it was decided not to follow the study protocol 
and to leave the study. The data of this patient were not used for 
the analysis. Twenty-one women were induced, resulting in vaginal 
delivery in seven women.
In the temporizing management group, significantly more women 
underwent an elective cesarean section. However, the overall cesarean 
section rate was equal and was in the whole group eventually 87.5%.
During admission, maximum mean arterial pressure was not sig-
nificantly different between the two groups of patients with a me-
dian of 117 mm Hg (IQR 108-123). Mean birthweight was slightly 
higher in the immediate delivery group (1440 g vs 1295 g) but was 
not statistically significant. This was despite the fact that there were 
more multiplets in the immediate delivery group. In the temporiz-
ing management group, more severe small-for-gestational-age (SGA) 
babies were born (71% vs 55%). In both groups together, 63% of all 
babies were SGA.
Table 4 describes the neonatal outcomes. Almost all neonates 
were admitted to the Neonatal Intensive Care Unit. In both groups, 
one neonate died postpartum. Severe neonatal complications oc-
curred in more than half of the babies. Overall, adverse neonatal 
outcome in the whole group was 54%. After the study was halted, 
only a minority of the neonates still had Bailey-3 assessments per-
formed at 2 years of corrected age. Neonates born after 30 weeks of 
gestation are not routinely assessed in the Netherlands. The remain-
ing numbers were too small to analyze.
Maternal outcomes are presented in Table 5. None of the women 
died. In the temporizing management group, one woman developed 
a placental abruption and one a pulmonary edema. HELLP syndrome, 
as defined above, was present or developed during admission in 41% 
of the women.
Separate analyses were done on only the singleton pregnancies 
(Tables S2-S5). The results of these analyses did not show differ-
ences with the previously described data.
4  | DISCUSSION
This randomized controlled open-label trial was stopped after 
35 months because of slow recruitment and long before reaching 
the intended number of participants. For several reasons, the re-
porting of the results from this trial has taken a prolonged period of 
time, but for ethical reasons we pursued publication.
The small number of inclusions makes it impossible to draw any 
conclusions. The only relevant findings were that participants who 
were randomized to temporizing management did not experience a 
clinically relevant prolongation of pregnancy, and that prespecified 
rules for termination of the pregnancy in the temporizing manage-
ment group were not met. The two severe maternal complications 
occurred in the temporizing management group. Not very surpris-
ingly, given this small and not relevant clinical difference in interval 
between randomization and delivery, neonatal complications were 
similar in both groups.
So far, four randomized controlled trials have been published 
in an identical population of patients (Table 1).10-13 Only the larg-
est trial12 included multiple pregnancies. All these trials started 
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TA B L E  2   Baseline characteristics. Data are presented as n (%), mean (SD) or median (range). If data are not available from all women, the 




(n = 30) (n = 26)
At start of pregnancy
Maternal age, yr (mean, SD) 29.2 (4.6) 28.7 (5.4)
Ethnicity
Caucasian 21 (70%) 15 (58%)
Other 9 (30%) 11 (42%)
Highest level of education
Primary or secondary school 0 (0%) 0 (0%)
Lower/medium professional education 6 (20%) 6 (21%)
Higher professional education/ university 2 (7%) 2 (8%)
Other/unknown 22 (73%) 16 (61%)
Current pregnancy:
Singleton 29 (97%) 22 (85%)
Twin 1 (3%) 3 (12%)
Triplet 0 (0%) 1 (4%)
Parity
Nulliparous 22 (73%) 12 (46%)
Primi- and multiparous 8 (27%) 14 (54%)
Preeclampsia in previous pregnancya  5/8 (63%) 9/14 (64%)
Blood pressure, at booking (mm Hg)
Systolic 118 (9.6) 135 (22.9)
Diastolic 74 (8.1) 80 (16.4)
BMI at booking >35 1 (3%) 4 (15%)
At start study
Gestational age (days) 214 (12.6) 216 (10.7)
Inclusion for:b 
Clinical symptoms 23 (77%) 17 (68%)
Laboratory abnormalities 10 (33%) 11 (42%)
Severe hypertension 20 (67%) 12 (46%)
Proteinuria (>300 mg/day) 28 (100%) 25 (100%)
Protein-to-creatinine ratio (mg/mmol) 184 (93-460) 73.5 (28-174)
Blood pressure, at inclusion (mm Hg)
Systolic 154 (30.1) 153 (17.0)
Diastolic 99 (10.8) 93 (10.6)
Smoking
No 24 (80%) 18 (69%)
Stopped in 1st or 2nd trimester 4/29 (14%) 4/25 (16%)
Unknown 2 (7%) 4 (15%)
Antihypertensive medication at study entry
Oral 27/29 (93%) 22 (85%)
Intravenous 15/29 (52%) 13/24 (54%)
Anticonvulsive medication (including magnesium sulfate) 25/26 (96%) 20 (77%)
BMI, body mass index.
aNumerator: primi- and multiparous women. 
bMultiple inclusion criteria possible. 
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similarly to our trial with inclusion at 28 weeks of gestation and con-
tinued until at least 32 weeks. Of the 56 included women, only six 
(11%) were randomized between 32 and 34 weeks of gestation in 
our trial. Maternal morbidity, HELLP syndrome, pulmonary edema 
and placental abruption occurred in our trial in 25 women of the 56 
women (45%). This is in line with the maternal complication rate of 
the largest and most recent study by Vigil-de-Garcia;12 however, 
that trial did not include women with HELLP syndrome, in con-
trast to our study, and not all women in that study had severe pre-
eclampsia. Also, the indications for delivery were different than in 
our trial. In particular, fetal growth restriction and the development 
of HELLP syndrome were not indications for delivery in our study. 
Since the inclusion criteria and rules for termination of pregnancy 
were clearly different from the previous trials, this trial contributes 




(95% CI) P value(n = 30) (n = 25)
Gestational age at delivery (weeks) 31.1 (29.3-33.0) 30.9 (30.1-32.3) 0.14 (−1.00-1.29)a  .93
Time randomization to delivery (days) 3 (2-6) 1 (0-2) −2 (-1 to -3) c  .0004
Total number of children born 31 31 — —
Stillbirth 0/31 (0%) 0/31 (0%) — —
Gender, girls 19/31 (61%) 13/31 (42%) —
Onset of labor:
Spontaneous 0 (0%) 0 (0%) — —
Induction 8 (27%) 14 (56%) 2.10 (1.06-4.18) .03
Elective cesarean section 22 (73%) 11 (44%) 0.60 (0.37-0.98) .03
Indication for induction
Randomization 0/8 (0%) 1/13 (8%) — —
Fetal condition 4/8 (50%) 10/13(77%) n/c —
Maternal condition 4/8 (50%) 0/13 (0%) n/c —
Other 0/8 (0.0%) 2/13 (15%) n/c —
Indication for cesarean section
Randomization 0/22 (0%) 7/11 (78%) n/c —
Fetal condition 7/22 (32%) 1/11 (9%) n/c —
Maternal condition 15/22 (68%) 3/11 (27%) n/c —
Other 0/22 (0%) 0/11 (0%) n/c —
Mode of delivery
Vaginal delivery 3 (10%) 4 (15%) 1.06 (0.87-1.30) .69b 
OVD 0 (0%) 0 (0%) — —
Cesarean section (elective and emergency) 27 (90%) 22 (85%) 0.94 (0.77-1.15) .69
Postpartum blood loss (mL) 400 (300-500) 400 (300-500) 0 (−100-100) c  .90
Postpartum hemorrhage 3 (10%) 2 (8%)
Birthweight (g) 1294 (386) 1,440 (297) 145 (−31.0-321.3) a  .10
Small for gestational age d 
<5th percentile 19 10 0.53 (0.29-0.94) .03
<10th percentile 22 17 0.77 (0.52-1.14) .20
Large for gestational age d 
>90th percentile 2 4 2.00 (0.39-10.13) .67b 
>95th percentile 2 4 2.00 (0.39-10.13) .67b 
OVD, operative vaginal delivery.
aMean difference between groups with 95% CI (two -sample t-test). 
bFisher's exact test. 
cHodges-Lehmann estimator and Mann-Whitney-Wilcoxon test. 
dPercentile groups are not mutually exclusive. 
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to the knowledge of the management of this category of patients. 
The prolongation of 2 days in our trial is not in line with the findings 
of the most recent and largest trial, which found a prolongation of 
8.1 days.12 But, as already mentioned, the inclusion criteria of this 
trial were different from our trial. Differences in patient character-
istics and severity of disease differed between our and prior studies 
and may account for the shorter randomization-to-delivery interval 
in our temporizing management group. Omitting the one patient 
in the immediate delivery group that left the study would have in-
creased the randomization-delivery interval to almost 3 days. This 
is still shorter than any of the other studies but in at least three of 
those studies, HELLP syndrome was a contraindication for inclu-
sion. Also, the development of HELLP syndrome was not a reason 
for termination of pregnancy in our study. The relative safety of this 
management was earlier described in a study comparing patients 
with severe preeclampsia with and without HELLP syndrome with 
an onset before 28 weeks.18 In our study, more than one-third of 
the women had laboratory abnormalities consistent with the fea-
tures of HELLP syndrome. A subanalysis of women with HELLP syn-








value(n = 31) (n = 30)
Neonatal death 1 (3%) 1 (3%) 0.97 (0.06-14.8) .98a 
Admission neonate to intensive 
care unit
29 (94%) 30 (100%) 0.94 (0.85-1.02) 1.00a 
Indication for NICU admission:
Hypoglycemia 2 (6%) 0 (0%) — —
Respiratory distress 
syndrome
13 (42%) 9 (29%) 0.69 (0.35-1.38) .30
Necrotizing enterocolitis 
(>stage 1)
2 (6%) 1 (3%) 0.50 (0.05-5.23) 1.00a 
Neonatal infection/sepsis 5 (16%) 6 (19%) 1.20 (0.41-3.52) 1.00a 
Intraventricular hemorrhage 
(>grade 2)
1 (3%) 1 (3%) 1.00 (0.07-15.3) 1.00a 
Periventricular leukomalacia 
(>grade 1)
1 (3%) 3 (10%) 3.00 (0.33-7.29) .61a 
Adverse perinatal outcome 16 (52%) 17 (55%) 1.06 (0.67-1.70) .80
NICU, Neonatal Intensive Care Unit.
aFisher's exact test. 
TA B L E  4   Neonatal outcomes 
(intention-to-treat). Data are n (%) or mean 









value(n = 30) (n = 25)
Eclampsia 0 0 n/a
Pulmonary edema 1 (3%) 0 n/a
Liver hematoma 0 0 n/a
HELLP syndrome 7 (23%) 9 (35%) 0.67 (0.29-1.56) .35
Hemolysis 0 1 (4%) n/a
Low plateletsb  3 (10%) 4 (16%) 0.65 (0.16-2.64) .69
Abnormal liver function 
testsc 
7 (23%) 7 (27%) 0.87 (0.35-2.15) .76
Placental abruption 1 (3%) 0 n/a
Maternal death 0 0 n/a
Women with maternal 
complicationsa 
9 (30%) 9 (36%) 0.83 (0.39-1.78) .64
aMultiple inclusion criteria possible. 
b≤100.103/mm3. 
cALAT ≥70 or ASAT ≥70 U/L. 
TA B L E  5   (Adverse) maternal outcomes 
(intention-to-treat)
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A recent Cochrane review and meta-analysis evaluated these 
four trials, the present trial (congress abstract) and a subset from the 
Growth Restriction Intervention Trial (GRIT).19,20 It was concluded 
that temporizing management under strict regulation is safe and may 
be associated with decreased morbidity for the neonate. The latter 
was suggested but is mainly based on the two oldest studies in this 
review. The most recent and largest study by Vigil-De Gracia did not 
find neonatal benefits with expectant management.12 Also, in this 
review, 262 women were included from GRIT trial.20 The women 
who were selected from this trial were included in the trial between 
24 and 34 weeks of gestation but their clinical diagnosis did not meet 
the criteria for early-onset severe preeclampsia as used in our trial 
and the other four earlier mentioned trials. Because of this aberrant 
inclusion period and lack of severe preeclampsia criteria, the findings 
from this trial should not have been incorporated in this review.
A previous meta-analysis published in 2017 included seven trials 
including our trial (at that time a conference abstract).21 The subject 
of this meta-analysis was expectant management vs elective deliv-
ery in preeclamptic patients during several periods of pregnancy. 
The data of our study could be used in this meta-analysis only in the 
case of placental abruption. The authors concluded that the chance 
of placental abruption was halved by elective delivery in women 
with early-onset severe preeclampsia (RR 0.43; 95% CI 0.19-0.98).
The most important limitation of this study is that the goal of 
included patients was not reached. It proved to be very difficult to 
obtain informed consent from eligible patients. Preeclampsia and 
its management are linked to strong personal views, both for doc-
tors and their patients. Also, many women could not be randomized 
because of the perceived necessity to deliver before randomization 
could take place. Although randomization was also stratified for a 
gestational age before or after 31 weeks, the numbers were too 
small for calculations and it was not possible to draw conclusions 
from these subgroups.
When designing this trial, adverse neonatal outcome in the sur-
viving neonates was estimated to be 12%, which was based on a pre-
vious study.17 However, in our study, adverse neonatal outcome was 
more than 50% in both groups. The main difference with the previ-
ous study was that also respiratory distress syndrome, necrotizing 
enterocolitis and proven sepsis were incorporated under adverse 
neonatal outcomes in this trial. After removing these parameters, 
the percentages of adverse neonatal outcome in both groups were 
comparable to the previous study and no differences were seen 
between the groups. Nevertheless, adverse neonatal outcome was 
comparable to that in the MEXPRE Latin study.12 Recalculation of 
the number of participants that would have been required to obtain 
80% power for a study with a composite neonatal morbidity of 50% 
resulted in a total of 2474 subjects. It is obvious that a randomized 
controlled trial on this subject of this magnitude will never be fea-
sible. This would also be the case were such a trial be performed in 
an international setting because of the different management proto-
cols. There also should be a larger commitment to the necessity of 
the trial, both in doctors and patients, to obtain a higher recruitment 
rate than 50%.
One strength of this trial is that temporizing management under 
observation with strict rules looks safe in this period of gestation in 
women with severe preeclampsia. Another strength of this trial are 
the strict inclusion criteria. Only women with severe preeclampsia 
were included. This may be the explanation for the large number of 
SGA cases. The largest other study found 21.7% and 9.4% of SGA 
babies.12 Our large percentage may have initiated the large percent-
age of cesarean sections on fetal indication.
5  | CONCLUSION
Because of lack of power and lack of difference in treatment be-
tween immediate delivery vs temporizing management in this study 
among women with early-onset severe preeclampsia, no conclusions 
can be drawn as to which management provides a better balance of 
maternal complications vs infant outcome. This topic warrants fur-
ther research, but any new study should address the issue of treat-
ment preference among clinicians and their patients. New treatment 
options for preeclampsia currently under investigation may lead 
to new insights into prolongation of pregnancy in this category of 
women.22
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